To be held between 5-7 November 2015 at Barcelona, Spain
Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during 5-7 November 2015 at Barcelona, Spain.During CTAD- 2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.
Powered by Capital Market - Live News
